Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2013

01.02.2013 | Original Article

Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases

verfasst von: Michiaki Karita, Hiroyuki Tsuchiya, Norio Yamamoto, Toshiharu Shirai, Katsuhiro Hayashi, Hideji Nishida

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Clear cell sarcoma is a rare malignant tumor of soft tissue which is most commonly encountered in the extremities, especially in the foot and ankle. This tumor is slow-growing and looks like a benign tumor; it is therefore often treated inadequately and its high rate of recurrence and metastases results in a poor prognosis. Caffeine has been used as a chemotherapy potentiator that inhibits DNA damage repair and enhances the cytocidal effects of anti-cancer drugs. This study reports the effect of caffeine-potentiated chemotherapy for clear cell sarcoma in five patients.

Methods

Caffeine-potentiated chemotherapy was administered to five patients with clear cell sarcoma. Three to five courses of intra-arterial chemotherapy using cisplatin, doxorubicin and caffeine were administered preoperatively, at 3-week intervals. Conservatively, wide margin surgery was performed following the preoperative chemotherapy. Intravenous cisplatin and doxorubicin with caffeine were administered three to six times to the patients who responded to the preoperative chemotherapy. This study evaluated the response to chemotherapy, recurrence, metastasis and the overall prognosis in these five patients.

Results

Four of the eligible patients responded to preoperative chemotherapy. Local recurrence occurred in only one of the five patients. Distant metastasis newly developed in one patient. All five patients survive.

Conclusion

Caffeine-potentiated chemotherapy can be effective treatment for clear cell sarcoma not only as initial therapy, but also as salvage therapy.
Literatur
1.
Zurück zum Zitat Enzinger FM, Weiss SW, Goldblum JR (2001) Soft tissue tumors, 4th edn. Mosby, St. Louis, pp 1241–1250 Enzinger FM, Weiss SW, Goldblum JR (2001) Soft tissue tumors, 4th edn. Mosby, St. Louis, pp 1241–1250
2.
Zurück zum Zitat Enzinger FM (1965) Clear cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18:1163–1174PubMedCrossRef Enzinger FM (1965) Clear cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18:1163–1174PubMedCrossRef
3.
Zurück zum Zitat Tsuneyoshi M, Enjoji M, Kubo T (1978) Clear cell sarcoma of tendons and aponeuroses. A comparative study of 13 cases with provisional subgrouping into the melanotic and synovial types. Cancer 42:243–252PubMedCrossRef Tsuneyoshi M, Enjoji M, Kubo T (1978) Clear cell sarcoma of tendons and aponeuroses. A comparative study of 13 cases with provisional subgrouping into the melanotic and synovial types. Cancer 42:243–252PubMedCrossRef
4.
Zurück zum Zitat Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM et al (2001) Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer 84:535–538PubMedCrossRef Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM et al (2001) Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer 84:535–538PubMedCrossRef
5.
Zurück zum Zitat Zucman J, Delattre O, Desmaze C et al (1993) EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4:341–345PubMedCrossRef Zucman J, Delattre O, Desmaze C et al (1993) EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4:341–345PubMedCrossRef
6.
Zurück zum Zitat Pavlidis NA, Fisher C, Wiltshaw E (1984) Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer 54:1412–1417PubMedCrossRef Pavlidis NA, Fisher C, Wiltshaw E (1984) Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer 54:1412–1417PubMedCrossRef
7.
Zurück zum Zitat Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop 204:9–24PubMed Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop 204:9–24PubMed
8.
Zurück zum Zitat Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18:657–666PubMed Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18:657–666PubMed
9.
Zurück zum Zitat Tsuchiya H, Tomita K, Yamamoto N et al (1998) Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft tissue sarcomas. Anticancer Res 18:3651–3656PubMed Tsuchiya H, Tomita K, Yamamoto N et al (1998) Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft tissue sarcomas. Anticancer Res 18:3651–3656PubMed
10.
Zurück zum Zitat Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop 358:27–35PubMed Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop 358:27–35PubMed
11.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
12.
Zurück zum Zitat Jacobs IA, Chang CK, Guzman G et al (2004) Clear cell sarcoma: an institutional review. Am Surg 70:300–303PubMed Jacobs IA, Chang CK, Guzman G et al (2004) Clear cell sarcoma: an institutional review. Am Surg 70:300–303PubMed
13.
Zurück zum Zitat Kuiper DR, Hoekstra HJ, Veth RPH et al (2003) The management of clear cell sarcoma. EJSO 29:568–570PubMedCrossRef Kuiper DR, Hoekstra HJ, Veth RPH et al (2003) The management of clear cell sarcoma. EJSO 29:568–570PubMedCrossRef
14.
Zurück zum Zitat Ferrari A, Casanova M, Bisogno G et al (2002) Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German soft tissue sarcoma cooperative group. Cancer 94:3269–3276PubMedCrossRef Ferrari A, Casanova M, Bisogno G et al (2002) Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German soft tissue sarcoma cooperative group. Cancer 94:3269–3276PubMedCrossRef
15.
Zurück zum Zitat Finley JW, Hanypsiak B, McGrath B et al (2001) Clear cell sarcoma: the Roswell Park experience. J Surg Oncol 77:16–20PubMedCrossRef Finley JW, Hanypsiak B, McGrath B et al (2001) Clear cell sarcoma: the Roswell Park experience. J Surg Oncol 77:16–20PubMedCrossRef
16.
Zurück zum Zitat Lucas DR, Nascimento AG, Sim FH (1992) Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol 16:1197–1204PubMedCrossRef Lucas DR, Nascimento AG, Sim FH (1992) Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol 16:1197–1204PubMedCrossRef
17.
Zurück zum Zitat Radstone DJ, Revell PA, Path MRC et al (1979) Clear cell sarcoma of tendons and aponeuroses treated with bleomycin and vincristine. Br J Radiol 52:238–241PubMedCrossRef Radstone DJ, Revell PA, Path MRC et al (1979) Clear cell sarcoma of tendons and aponeuroses treated with bleomycin and vincristine. Br J Radiol 52:238–241PubMedCrossRef
18.
Zurück zum Zitat Steger GG, Wrba F, Mader R et al (1991) Complete remission of metastasized clear cell sarcoma of tendons and aponeuroses. Eur J Cancer 27:254–256PubMedCrossRef Steger GG, Wrba F, Mader R et al (1991) Complete remission of metastasized clear cell sarcoma of tendons and aponeuroses. Eur J Cancer 27:254–256PubMedCrossRef
19.
Zurück zum Zitat Tomita K, Tsuchiya H (1989) Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 80:83–88PubMedCrossRef Tomita K, Tsuchiya H (1989) Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 80:83–88PubMedCrossRef
20.
Zurück zum Zitat Tomita K, Tsuchiya H (1989) Enhancement of cytocidal and antitumor effect of CDDP by caffeine in human osteosarcoma. Clin Ther 11:43–52PubMed Tomita K, Tsuchiya H (1989) Enhancement of cytocidal and antitumor effect of CDDP by caffeine in human osteosarcoma. Clin Ther 11:43–52PubMed
21.
Zurück zum Zitat Yasutake H, Tsuchiya H, Tomita K et al (1995) Inhibitory effect of caffeine on potentially lethal damage repair in CDDP-treated human osteosarcoma cells. Anticancer Res 15:831–838PubMed Yasutake H, Tsuchiya H, Tomita K et al (1995) Inhibitory effect of caffeine on potentially lethal damage repair in CDDP-treated human osteosarcoma cells. Anticancer Res 15:831–838PubMed
22.
Zurück zum Zitat Tsuchiya H, Mori Y, Ueda Y et al (2000) Sensitization and caffeine potentiation of CDDP cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 20:235–242PubMed Tsuchiya H, Mori Y, Ueda Y et al (2000) Sensitization and caffeine potentiation of CDDP cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 20:235–242PubMed
23.
Zurück zum Zitat Takeda A, Tsuchiya H, Tajino T et al (2005) An experimental study on the therapeutic effect of consecutive low-dose CDDP with caffeine in sarcoma-bearing mice. Anticancer Res 25:2777–2784PubMed Takeda A, Tsuchiya H, Tajino T et al (2005) An experimental study on the therapeutic effect of consecutive low-dose CDDP with caffeine in sarcoma-bearing mice. Anticancer Res 25:2777–2784PubMed
24.
Zurück zum Zitat Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef
25.
Zurück zum Zitat Tsuchiya H, Yamamoto N, Asada N et al (2000) Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res 20:2137–2143PubMed Tsuchiya H, Yamamoto N, Asada N et al (2000) Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res 20:2137–2143PubMed
26.
Zurück zum Zitat Hayashi M, Tsuchiya H, Yamamoto N et al (2005) Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 25:2399–2405PubMed Hayashi M, Tsuchiya H, Yamamoto N et al (2005) Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 25:2399–2405PubMed
27.
Zurück zum Zitat Takeuchi A, Tsuchiya H, Yamamoto N et al (2007) Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res 27:3489–3496PubMed Takeuchi A, Tsuchiya H, Yamamoto N et al (2007) Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res 27:3489–3496PubMed
Metadaten
Titel
Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases
verfasst von
Michiaki Karita
Hiroyuki Tsuchiya
Norio Yamamoto
Toshiharu Shirai
Katsuhiro Hayashi
Hideji Nishida
Publikationsdatum
01.02.2013
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0337-9

Weitere Artikel der Ausgabe 1/2013

International Journal of Clinical Oncology 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.